The US Food and Drug Administration (FDA) has granted premarket approval (PMA) to Zoll Medical’s new Hospital Wearable Defibrillator (HWD).
The approval allows the firm to market and distribute the defibrillator in the US. The device was developed to protect patients at risk of ventricular tachycardia (VT) or ventricular fibrillation (VF) and it features automatic detection and immediate treatment, enabling continuous protection day or night.
